Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis
Author:
Publisher
Informa Healthcare
Subject
Health Policy
Link
http://www.tandfonline.com/doi/pdf/10.3111/13696998.2014.912987
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Budget impact models for lung cancer interventions: A systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09
2. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations;Journal of Managed Care & Specialty Pharmacy;2023-02
3. A systematic review of the budget impact analyses for antitumor drugs of lung cancer;Cost Effectiveness and Resource Allocation;2020-12
4. Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?;Cardio-Oncology;2018-06-15
5. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan;Journal of Managed Care & Specialty Pharmacy;2018-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3